Grant ID RP150282
Awarded On February 18, 2015
Title Mechanisms of de novo and acquired resistance to therapeutic treatment of bone-metastatic prostate cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Gary Gallick
Cancer Sites Prostate
Contracted Amount $900,000
Lay Summary

Many new therapeutics have been approved that prolong the lives of men who have prostate cancer that has metastasized to the bone. However, the effects of these drugs are often short-lived, and tumor cells that are resistant to the therapy regrow, leading to death of the patient. If the mechanisms by which resistance develops were better understood, new drugs or drug combinations may be developed that would delay or prevent therapy resistance. Our studies have focused on mechanisms of resistance with the goal of developing such efficacious drug combinations. An unusual property of prostate cancer bone metastases is that they promote the formation of new bone. In doing so, tumors interacting ...

Read More